Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study.

Young, J; Scherrer, A U; Günthard, H F; Opravil, M; Yerly, S; Böni, J; Rickenbach, M; Fux, C A; Cavassini, M; Bernasconi, E; Vernazza, P; Hirschel, B; Battegay, M; Bucher, H C

Young, J; Scherrer, A U; Günthard, H F; Opravil, M; Yerly, S; Böni, J; Rickenbach, M; Fux, C A; Cavassini, M; Bernasconi, E; Vernazza, P; Hirschel, B; Battegay, M; Bucher, H C.

Affiliation

Young J; Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland. jyoung@uhbs.ch

HIV Med ; 12(5): 299-307, 2011 May.

Article in En | MEDLINE | ID: mdl-20955357

Subject(s)

HIV Infections/drug therapy; HIV Protease Inhibitors/therapeutic use; HIV-1/drug effects; Sulfonamides/therapeutic use; Bayes Theorem; CD4 Lymphocyte Count; Cohort Studies; Darunavir; Drug Resistance, Viral; Female; HIV Infections/immunology; Humans; Male; Middle Aged; Prospective Studies; Risk Factors; Salvage Therapy; Treatment Outcome; Viral Load

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sulfonamides / HIV Infections / HIV-1 / HIV Protease Inhibitors Type of study: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans / Male / Middle aged Language: En Journal: HIV Med Year: 2011 Document type: Article

Fulltext

XML

PubMed Links

Search on Google